Better Buy: Invitae vs. Illumina
Two sets of numbers tell you a lot about how Invitae (NYSE: NVTA) and Illumina (NASDAQ: ILMN) compare. First, there's the pair of market caps. Invitae's market cap of under $6 billion is only a fraction of Illumina's market cap of nearly $45 billion. But Invitae's shares have delivered a year-to-date gain of more than 160% versus a loss of 7% for Illumina.
These numbers paint the picture of a small up-and-coming genetics player and a large, established, slower-growth industry leader. But how accurate is that picture? And which of these healthcare stocks is the better pick for long-term investors?
Image source: Getty Images.
Source Fool.com
